Who we are.

Our leadership team has extensive experience in developing RNA therapeutics and building successful biopharmaceutical companies.

Paris Panayiotopoulos

Executive Chairman

Paris most recently served as President and CEO of ARIAD Pharmaceuticals through its acquisition by Takeda in 2017. Prior to ARIAD, Paris was President of EMD Serono, the North American biopharmaceutical business of Merck KGaA, as well as President of Merck Serono in Japan and the Serono Research & Development Institute. He has led partnerships with Pfizer, Bristol Myers Squibb, Eli Lilly & Co., Dainippon Sumitomo Pharma, Mitsubishi Tanabe, Otsuka, Incyte, and others.

Bo Rode Hansen, MBA, Ph.D.

President and Chief Executive Officer

Bo joined Genevant from Roche, where he served as Global Head of RNA Therapeutics and General Manager of the Roche Innovation Center Copenhagen. Prior to Roche, Bo was Executive Vice President and Head of Drug Discovery & Alliance Management at Santaris Pharma A/S through the company’s acquisition by Roche in 2014. Over the course of his career, Bo has led over 50 RNA therapeutic discovery programs which have yielded 10 clinical candidates and over 40 patents and patent applications.

Peter Lutwyche, PhD

Chief Technology Officer & Vancouver Site Head

Peter most recently served as Chief Technology Officer at Arbutus Biopharma Corporation where he led the development of the company’s nucleic acid-delivery technology. Earlier in his career, he was Head of Pharmaceutical Development at QLT where he contributed to the development and commercialization of VISUDYNE®. Peter has over 20 years of experience in the field of nucleic acid-based products.

Constantine Linnik, JD, PhD

General Counsel & SVP, Intellectual Property & Legal Affairs

Constantine was most recently Partner at Nutter, McClennen & Fish LLP where he represented and advised clients in IP-related contracts as well as proceedings before national and international patent offices. He was previously Senior Corporate Counsel and Lead Patent Counsel for the Oligonucleotide Therapeutics Unit at Pfizer. He holds a PhD in Biophysics from the Boston University School of Medicine and began his legal career at Cooley LLP and Finnegan where he prosecuted over 1,200 biopharma patent applications in the U.S. and abroad.

James Heyes, PhD

SVP, Technology Development

James brings expertise in lipid chemistry and nucleic acid drug delivery with over 17 years of experience in the field. He is a key inventor of next generation lipid nanoparticle and ligand conjugate technology, with more than 20 issued and published U.S. patents in the area. He designed the lipid components enabling the first demonstration of RNA interference in primates, and subsequently the advance of 13 clinical candidates. As Vice President of Drug Delivery at Arbutus, he led a multidisciplinary team spanning early discovery to pharmaceutical development.